IDEXX Laboratories, Inc. (NASDAQ: IDXX) Stock Competitors & Peer Comparison
See IDXX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IDXX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IDXX | $560.38 | -1.13% | 44.1B | 39.41 | $14.22 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.67% |
| TMO | $673.82 | -0.40% | 249.2B | 29.10 | $23.16 | +0.27% |
| DHR | $230.50 | +0.33% | 162B | 28.88 | $7.98 | +0.67% |
| NTRA | $403.95 | +0.64% | 58.2B | -306.02 | -$1.32 | N/A |
| A | $173.07 | -0.47% | 48.8B | 29.78 | $5.81 | +0.59% |
| IQV | $279.36 | +0.37% | 46B | 23.03 | $12.13 | N/A |
| WAT | $453.67 | -0.42% | 44.5B | 33.16 | $13.68 | N/A |
| ILMN | $269.42 | +0.01% | 40.7B | 53.56 | $5.03 | N/A |
| MTD | $1,670.29 | -0.85% | 33.4B | 38.35 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
IDXX vs DHR-PB Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, IDXX's ROE is +0.72%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, IDXX is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
IDXX vs TMO Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, TMO has a market cap of 249.2B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while TMO trades at $673.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas TMO's P/E ratio is 29.10. In terms of profitability, IDXX's ROE is +0.72%, compared to TMO's ROE of +0.13%. Regarding short-term risk, IDXX is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
IDXX vs DHR Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, DHR has a market cap of 162B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while DHR trades at $230.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas DHR's P/E ratio is 28.88. In terms of profitability, IDXX's ROE is +0.72%, compared to DHR's ROE of +0.08%. Regarding short-term risk, IDXX is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
IDXX vs NTRA Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, NTRA has a market cap of 58.2B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while NTRA trades at $403.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas NTRA's P/E ratio is -306.02. In terms of profitability, IDXX's ROE is +0.72%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, IDXX is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
IDXX vs A Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, A has a market cap of 48.8B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while A trades at $173.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas A's P/E ratio is 29.78. In terms of profitability, IDXX's ROE is +0.72%, compared to A's ROE of +0.20%. Regarding short-term risk, IDXX is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
IDXX vs IQV Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, IQV has a market cap of 46B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while IQV trades at $279.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas IQV's P/E ratio is 23.03. In terms of profitability, IDXX's ROE is +0.72%, compared to IQV's ROE of +0.22%. Regarding short-term risk, IDXX is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check IQV's competition here
Waters Corporation (NYSE: WAT)
IDXX vs WAT Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, WAT has a market cap of 44.5B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while WAT trades at $453.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas WAT's P/E ratio is 33.16. In terms of profitability, IDXX's ROE is +0.72%, compared to WAT's ROE of +0.02%. Regarding short-term risk, IDXX is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check WAT's competition here
Illumina, Inc. (NASDAQ: ILMN)
IDXX vs ILMN Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, ILMN has a market cap of 40.7B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while ILMN trades at $269.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas ILMN's P/E ratio is 53.56. In terms of profitability, IDXX's ROE is +0.72%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, IDXX is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
IDXX vs MTD Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, MTD has a market cap of 33.4B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while MTD trades at $1,670.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas MTD's P/E ratio is 38.35. In terms of profitability, IDXX's ROE is +0.72%, compared to MTD's ROE of -12.00%. Regarding short-term risk, IDXX is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
IDXX vs DGX Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, DGX has a market cap of 26.7B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while DGX trades at $241.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas DGX's P/E ratio is 23.85. In terms of profitability, IDXX's ROE is +0.72%, compared to DGX's ROE of +0.15%. Regarding short-term risk, IDXX is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
IDXX vs LH Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, LH has a market cap of 26.7B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while LH trades at $328.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas LH's P/E ratio is 19.53. In terms of profitability, IDXX's ROE is +0.72%, compared to LH's ROE of +0.12%. Regarding short-term risk, IDXX is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
IDXX vs GH Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, GH has a market cap of 22.7B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while GH trades at $169.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas GH's P/E ratio is -48.45. In terms of profitability, IDXX's ROE is +0.72%, compared to GH's ROE of +2.11%. Regarding short-term risk, IDXX is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
IDXX vs EXAS Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas EXAS's P/E ratio is -95.37. In terms of profitability, IDXX's ROE is +0.72%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, IDXX is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
IDXX vs MEDP Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, MEDP has a market cap of 18.7B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while MEDP trades at $669.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas MEDP's P/E ratio is 39.23. In terms of profitability, IDXX's ROE is +0.72%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, IDXX is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
IDXX vs RVTY Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, RVTY has a market cap of 17.7B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while RVTY trades at $158.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas RVTY's P/E ratio is 29.67. In terms of profitability, IDXX's ROE is +0.72%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, IDXX is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
IDXX vs ILMNV Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas ILMNV's P/E ratio is N/A. In terms of profitability, IDXX's ROE is +0.72%, compared to ILMNV's ROE of N/A. Regarding short-term risk, IDXX is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
IDXX vs CRL Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, CRL has a market cap of 16.6B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while CRL trades at $345.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas CRL's P/E ratio is 34.87. In terms of profitability, IDXX's ROE is +0.72%, compared to CRL's ROE of -0.08%. Regarding short-term risk, IDXX is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check CRL's competition here
PerkinElmer, Inc. (NYSE: PKI)
IDXX vs PKI Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas PKI's P/E ratio is 41.45. In terms of profitability, IDXX's ROE is +0.72%, compared to PKI's ROE of +0.03%. Regarding short-term risk, IDXX is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
IDXX vs ICLR Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, ICLR has a market cap of 14.3B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while ICLR trades at $185.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas ICLR's P/E ratio is 15.11. In terms of profitability, IDXX's ROE is +0.72%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, IDXX is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
IDXX vs QGEN Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while QGEN trades at $50.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas QGEN's P/E ratio is 20.82. In terms of profitability, IDXX's ROE is +0.72%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, IDXX is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
IDXX vs GRAL Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while GRAL trades at $132.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas GRAL's P/E ratio is -13.59. In terms of profitability, IDXX's ROE is +0.72%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, IDXX is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
IDXX vs RDNT Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while RDNT trades at $70.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas RDNT's P/E ratio is 152.91. In terms of profitability, IDXX's ROE is +0.72%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, IDXX is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
IDXX vs SHC Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while SHC trades at $18.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas SHC's P/E ratio is 18.85. In terms of profitability, IDXX's ROE is +0.72%, compared to SHC's ROE of +0.27%. Regarding short-term risk, IDXX is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
IDXX vs BLLN Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, BLLN has a market cap of 5.1B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while BLLN trades at $107.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas BLLN's P/E ratio is 153.96. In terms of profitability, IDXX's ROE is +0.72%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, IDXX is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
IDXX vs SYNH Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas SYNH's P/E ratio is 61.40. In terms of profitability, IDXX's ROE is +0.72%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, IDXX is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
IDXX vs VCYT Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while VCYT trades at $47.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas VCYT's P/E ratio is 23.97. In terms of profitability, IDXX's ROE is +0.72%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, IDXX is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
IDXX vs CDNA Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, CDNA has a market cap of 3.6B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while CDNA trades at $69.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas CDNA's P/E ratio is 82.39. In terms of profitability, IDXX's ROE is +0.72%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, IDXX is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
IDXX vs OLK Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas OLK's P/E ratio is -96.59. In terms of profitability, IDXX's ROE is +0.72%, compared to OLK's ROE of -0.07%. Regarding short-term risk, IDXX is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
IDXX vs NEO Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while NEO trades at $16.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas NEO's P/E ratio is 127.62. In terms of profitability, IDXX's ROE is +0.72%, compared to NEO's ROE of -0.06%. Regarding short-term risk, IDXX is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check NEO's competition here
Personalis, Inc. (NASDAQ: PSNL)
IDXX vs PSNL Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while PSNL trades at $15.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas PSNL's P/E ratio is -14.52. In terms of profitability, IDXX's ROE is +0.72%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, IDXX is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check PSNL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
IDXX vs WGS Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, WGS has a market cap of 1.7B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while WGS trades at $56.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas WGS's P/E ratio is 155.97. In terms of profitability, IDXX's ROE is +0.72%, compared to WGS's ROE of -0.39%. Regarding short-term risk, IDXX is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check WGS's competition here
OPKO Health, Inc. (NASDAQ: OPK)
IDXX vs OPK Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while OPK trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas OPK's P/E ratio is -18.33. In terms of profitability, IDXX's ROE is +0.72%, compared to OPK's ROE of -0.06%. Regarding short-term risk, IDXX is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
IDXX vs CSTL Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while CSTL trades at $33.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas CSTL's P/E ratio is -50.12. In terms of profitability, IDXX's ROE is +0.72%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, IDXX is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
IDXX vs GRALV Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas GRALV's P/E ratio is N/A. In terms of profitability, IDXX's ROE is +0.72%, compared to GRALV's ROE of N/A. Regarding short-term risk, IDXX is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
IDXX vs MYGN Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, MYGN has a market cap of 557.6M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while MYGN trades at $5.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas MYGN's P/E ratio is -44.85. In terms of profitability, IDXX's ROE is +0.72%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, IDXX is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check MYGN's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
IDXX vs FLGT Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, FLGT has a market cap of 553.1M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while FLGT trades at $20.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas FLGT's P/E ratio is 2010.00. In terms of profitability, IDXX's ROE is +0.72%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, IDXX is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check FLGT's competition here
Global Cord Blood Corporation (NYSE: CO)
IDXX vs CO Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas CO's P/E ratio is 5.06. In terms of profitability, IDXX's ROE is +0.72%, compared to CO's ROE of +0.11%. Regarding short-term risk, IDXX is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
IDXX vs FLDM Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas FLDM's P/E ratio is -4.74. In terms of profitability, IDXX's ROE is +0.72%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, IDXX is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
IDXX vs XGN Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, XGN has a market cap of 176.1M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while XGN trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas XGN's P/E ratio is -8.98. In terms of profitability, IDXX's ROE is +0.72%, compared to XGN's ROE of -1.22%. Regarding short-term risk, IDXX is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check XGN's competition here
Biodesix, Inc. (NASDAQ: BDSX)
IDXX vs BDSX Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, BDSX has a market cap of 172.4M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while BDSX trades at $21.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas BDSX's P/E ratio is -6.68. In terms of profitability, IDXX's ROE is +0.72%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, IDXX is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check BDSX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
IDXX vs GTH Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas GTH's P/E ratio is -1.11. In terms of profitability, IDXX's ROE is +0.72%, compared to GTH's ROE of -1.01%. Regarding short-term risk, IDXX is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
IDXX vs GENE Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas GENE's P/E ratio is -38.25. In terms of profitability, IDXX's ROE is +0.72%, compared to GENE's ROE of -1.85%. Regarding short-term risk, IDXX is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
IDXX vs FRNM Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, FRNM has a market cap of 104.2M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while FRNM trades at $12.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas FRNM's P/E ratio is N/A. In terms of profitability, IDXX's ROE is +0.72%, compared to FRNM's ROE of N/A. Regarding short-term risk, IDXX is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
IDXX vs IMDX Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, IMDX has a market cap of 92.6M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while IMDX trades at $2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas IMDX's P/E ratio is -1.90. In terms of profitability, IDXX's ROE is +0.72%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, IDXX is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check IMDX's competition here
Precipio, Inc. (NASDAQ: PRPO)
IDXX vs PRPO Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, PRPO has a market cap of 37.1M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while PRPO trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas PRPO's P/E ratio is -31.92. In terms of profitability, IDXX's ROE is +0.72%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, IDXX is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
IDXX vs AKU Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas AKU's P/E ratio is -0.13. In terms of profitability, IDXX's ROE is +0.72%, compared to AKU's ROE of -5.32%. Regarding short-term risk, IDXX is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check AKU's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
IDXX vs QUCY Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, QUCY has a market cap of 23M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while QUCY trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas QUCY's P/E ratio is -0.05. In terms of profitability, IDXX's ROE is +0.72%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, IDXX is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check QUCY's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
IDXX vs BIAF Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, BIAF has a market cap of 17.6M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while BIAF trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas BIAF's P/E ratio is -0.33. In terms of profitability, IDXX's ROE is +0.72%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, IDXX is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check BIAF's competition here
MDxHealth S.A. (NASDAQ: MDXH)
IDXX vs MDXH Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, MDXH has a market cap of 17.5M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while MDXH trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas MDXH's P/E ratio is -0.25. In terms of profitability, IDXX's ROE is +0.72%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, IDXX is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check MDXH's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
IDXX vs CEMI Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas CEMI's P/E ratio is -0.63. In terms of profitability, IDXX's ROE is +0.72%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, IDXX is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
IDXX vs ENZ Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas ENZ's P/E ratio is -2.24. In terms of profitability, IDXX's ROE is +0.72%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, IDXX is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
IDXX vs PMD Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas PMD's P/E ratio is -5.24. In terms of profitability, IDXX's ROE is +0.72%, compared to PMD's ROE of -0.32%. Regarding short-term risk, IDXX is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
IDXX vs ME Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas ME's P/E ratio is -0.03. In terms of profitability, IDXX's ROE is +0.72%, compared to ME's ROE of -3.47%. Regarding short-term risk, IDXX is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
IDXX vs MYNZ Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, IDXX's ROE is +0.72%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, IDXX is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
IDXX vs BNR Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, BNR has a market cap of 12.5M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while BNR trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas BNR's P/E ratio is -13.59. In terms of profitability, IDXX's ROE is +0.72%, compared to BNR's ROE of -0.13%. Regarding short-term risk, IDXX is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
IDXX vs CHEK Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas CHEK's P/E ratio is -0.43. In terms of profitability, IDXX's ROE is +0.72%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, IDXX is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
IDXX vs CNTG Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas CNTG's P/E ratio is -0.23. In terms of profitability, IDXX's ROE is +0.72%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, IDXX is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
IDXX vs APDN Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas APDN's P/E ratio is -0.10. In terms of profitability, IDXX's ROE is +0.72%, compared to APDN's ROE of -7.23%. Regarding short-term risk, IDXX is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
IDXX vs NDRA Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while NDRA trades at $4.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas NDRA's P/E ratio is -0.70. In terms of profitability, IDXX's ROE is +0.72%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, IDXX is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
IDXX vs BIAFW Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, BIAFW has a market cap of 5.7M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while BIAFW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas BIAFW's P/E ratio is 0.61. In terms of profitability, IDXX's ROE is +0.72%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, IDXX is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
IDXX vs NVTA Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas NVTA's P/E ratio is -0.00. In terms of profitability, IDXX's ROE is +0.72%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, IDXX is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check NVTA's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
IDXX vs ADVB Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, ADVB has a market cap of 5.2M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while ADVB trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas ADVB's P/E ratio is -28.82. In terms of profitability, IDXX's ROE is +0.72%, compared to ADVB's ROE of -0.20%. Regarding short-term risk, IDXX is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check ADVB's competition here
LumiraDx Limited (NASDAQ: LMDXW)
IDXX vs LMDXW Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, IDXX's ROE is +0.72%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, IDXX is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
IDXX vs LMDX Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas LMDX's P/E ratio is -0.01. In terms of profitability, IDXX's ROE is +0.72%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, IDXX is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
IDXX vs DMTK Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas DMTK's P/E ratio is -0.04. In terms of profitability, IDXX's ROE is +0.72%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, IDXX is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
IDXX vs NOTV Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas NOTV's P/E ratio is -0.03. In terms of profitability, IDXX's ROE is +0.72%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, IDXX is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
IDXX vs SQL Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas SQL's P/E ratio is -0.40. In terms of profitability, IDXX's ROE is +0.72%, compared to SQL's ROE of -30.46%. Regarding short-term risk, IDXX is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
IDXX vs AWH Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas AWH's P/E ratio is -0.09. In terms of profitability, IDXX's ROE is +0.72%, compared to AWH's ROE of +1.62%. Regarding short-term risk, IDXX is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
IDXX vs ISPC Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, ISPC has a market cap of 2.1M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while ISPC trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas ISPC's P/E ratio is -0.03. In terms of profitability, IDXX's ROE is +0.72%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, IDXX is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
IDXX vs HTGM Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas HTGM's P/E ratio is -0.03. In terms of profitability, IDXX's ROE is +0.72%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, IDXX is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
IDXX vs BIOC Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas BIOC's P/E ratio is -0.01. In terms of profitability, IDXX's ROE is +0.72%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, IDXX is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
IDXX vs SQLLW Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, IDXX's ROE is +0.72%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, IDXX is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
IDXX vs WGSWW Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, IDXX's ROE is +0.72%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, IDXX is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
IDXX vs OCDX Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas OCDX's P/E ratio is -42.28. In terms of profitability, IDXX's ROE is +0.72%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, IDXX is similarly volatile compared to OCDX. This indicates similar risk in terms of short-term price fluctuations for IDXX.Check OCDX's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
IDXX vs MEUSW Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas MEUSW's P/E ratio is N/A. In terms of profitability, IDXX's ROE is +0.72%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, IDXX is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
IDXX vs NDRAW Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas NDRAW's P/E ratio is N/A. In terms of profitability, IDXX's ROE is +0.72%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, IDXX is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check NDRAW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
IDXX vs CHEKZ Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, IDXX's ROE is +0.72%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, IDXX is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check CHEKZ's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
IDXX vs BNGOW Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas BNGOW's P/E ratio is N/A. In terms of profitability, IDXX's ROE is +0.72%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, IDXX is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check BNGOW's competition here
Danaher Corporation (NYSE: DHR-PA)
IDXX vs DHR-PA Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, IDXX's ROE is +0.72%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, IDXX is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for IDXX.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
IDXX vs PRXL Comparison October 2026
IDEXX Laboratories, Inc. (NASDAQ: IDXX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDXX stands at 44.1B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, IDXX is priced at $560.38 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDXX currently has a P/E ratio of 39.41, whereas PRXL's P/E ratio is 42.97. In terms of profitability, IDXX's ROE is +0.72%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, IDXX is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for IDXX.Check PRXL's competition here